Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: A measurement system for evaluating athletes using a weighted resistance towing sled to which an athlete is connected using a harness and tether, is described, the measurement device comprising: a force sensing device located in the connection between the athlete and the sled, the force sensing device having a load cell, the force sensing device measuring the force exerted on the sled by the athlete; a second sensing device, the second sensing device having at least one accelerometer; and a communication device for communicating data from the sensing devices, wherein the second sensing device provides data for the calculation of at least linear velocity, linear acceleration and linear distance travelled.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.

Abstract: A vessel (1) for laying a pipeline (2), comprising a tower (3) which comprises a firing line (4) and is connected to the vessel by a hinge assembly (5) comprising a tower pivot axis (6), wherein: the tower is pivotable relative to the vessel about the tower pivot axis, during pipelaying the tower comprises an upper end and a lower end and the pipeline moves relative to the vessel along the firing line in a laying direction from the upper end towards the lower end, and the tower pivot axis is located at a distance D1 from said upper end as viewed in the laying direction, a system for abandoning and recovering the pipeline, wherein: the system comprises at least one line for lowering and raising a member configured to be connected to the pipeline, and the at least one line is supported by the hinge assembly and/or by the tower at a distance of at least ? D1 from said upper end as viewed in the laying direction.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: A vessel (1) for laying a pipeline (2), comprising a tower (3) which comprises a firing line (4) and is connected to the vessel by a hinge assembly (5) comprising a tower pivot axis (6), wherein: the tower is pivotable relative to the vessel about the tower pivot axis, during pipelaying the tower comprises an upper end and a lower end and the pipeline moves relative to the vessel along the firing line in a laying direction from the upper end towards the lower end, and the tower pivot axis is located at a distance D1 from said upper end as viewed in the laying direction, a system for abandoning and recovering the pipeline, wherein: the system comprises at least one line for lowering and raising a member configured to be connected to the pipeline, and the at least one line is supported by the hinge assembly and/or by the tower at a distance of at least ? D1 from said upper end as viewed in the laying direction.

Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.

Abstract: The invention relates to novel proteins with BAFF dominant negative antagonist, receptor antagonist activity and agonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of BAFF or APRIL-related disorders.

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract: The present invention describes antibodies that target CD5, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.